The Extraordinary General Assembly of GlaxoSmithKline approved to sell its consumer healthcare assets (not including real estate and machinery) and intangible assets at EGP 1.179 billion.
The Extraordinary General Assembly of GlaxoSmithKline approved to sell its consumer healthcare assets (not including real estate and machinery) and intangible assets at EGP 1.179 billion.